December 2, 2013
Ohio Cancer Research Associates, OCRA, an organization dedicated to the cure and prevention of the many forms of cancer, honored Stanton L. Gerson, MD, for his contributions to cancer research at the OCRA’s Singular Sensation ceremony and banquet on November 22, 2013.
Dr. Gerson was recognized for his substantial impact on patients and their families, his strong community advocacy and for his work in cancer research.
Dr. Stanton Gerson, MD, is the Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology, director of the Case Comprehensive Cancer Center, director of the Seidman Cancer Center at UH Case Medical Center, and director of the National Center for Regenerative Medicine.
Through Dr. Gerson’s leadership of the Case Comprehensive Cancer Center, more than 325 researchers from Case Western Reserve University, the Cleveland Clinic and University Hospitals work collaboratively to improve diagnosis, develop better treatments, or find cures.
In 2012, the Case Comprehensive Cancer Center enrolled more than 1,300 patients in clinical trials involving cancer treatment, screening, early detection, prevention or supportive care.
Dr. Gerson is responsible for breakthroughs that have either changed protocols – or hold the promise to do so, including a gene therapy strategy that may eliminate the need for high-dose, toxic therapy. His research has generated 16 patents in the area of gene therapy and cancer drug development.
Through his leadership and direction, the Case Comprehensive Cancer Center recently secured an overall rating of "outstanding" and a five-year renewal of its grant from the National Cancer Institute making the Cancer Center one of the outstanding points of pride for the City of Cleveland.
Established in 1982, Ohio Cancer Research Associates is an independent, statewide, nonprofit organization dedicated to the cure and prevention of the many forms of cancer and the reduction of its debilitating effects through aggressive basic seed money research, cancer information, and awareness.
The over $6.8 million in seed money provided by Ohio Cancer Research Associates has generated over $174.2 million in new money from other sources to continue basic cancer research on projects initially funded.